A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People ≥ 16 Years of Age Who Have Sex With Male Partners and Are at Risk for HIV Infection
The goal of this clinical study is to test how well the study drug, lenacapavir (LEN), works in reducing the risk of HIV.
Requirements to Enter Study:
ClinicalTrials.gov - https://classic.clinicaltrials.gov/ct2/show/NCT04925752
Gilead Purpose 2 Website - https://www.purposestudies.com/purpose2/#questionnaire